Comparison of AAV-Mediated Optogenetic Vision Restoration between Retinal Ganglion Cell Expression and ON Bipolar Cell Targeting.

Blindness CAG promoter Channelrhodopsin Optomotor response Retinal bipolar cell Retinal degenerative disease Retinal gene therapy knockout mouse model mGluR6 promoter pupillary light reflex

Journal

Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857

Informations de publication

Date de publication:
11 Sep 2020
Historique:
received: 15 05 2020
accepted: 19 05 2020
entrez: 18 6 2020
pubmed: 18 6 2020
medline: 18 6 2020
Statut: epublish

Résumé

The loss of photoreceptors in individuals with retinal degenerative diseases leads to partial or complete blindness. Optogenetic therapy is a promising approach for restoring vision to the blind. Multiple strategies have been employed by targeting genetically encoded light sensors, particularly channelrhodopsins, to surviving retinal neurons in animal models. In particular, the strategy of targeting retinal bipolar cells has commonly been expected to result in better vision than ubiquitous expression in retinal ganglion cells. However, a direct comparison of the channelrhodopsin-restored vision between these two strategies has not been performed. Here, we compared the restored visual functions achieved by adeno-associated virus (AAV)-mediated expression of a channelrhodopsin in ON-type bipolar cells and retinal ganglion cells driven by an improved mGluR6 promoter and a CAG promoter, respectively, in a blind mouse model by performing electrophysiological recordings and behavioral assessments. Unexpectedly, the efficacy of the restored vision based on light sensitivity and visual acuity was much higher following ubiquitous retinal ganglion cell expression than that of the strategy targeting ON-type bipolar cells. Our study suggests that, at least based on currently available gene delivery techniques, the expression of genetically encoded light sensors in retinal ganglion cells is likely a practical and advantageous strategy for optogenetic vision restoration.

Identifiants

pubmed: 32548211
doi: 10.1016/j.omtm.2020.05.009
pii: S2329-0501(20)30096-6
pmc: PMC7287188
doi:

Types de publication

Journal Article

Langues

eng

Pagination

15-23

Informations de copyright

© 2020 The Author(s).

Références

Physiol Rev. 1991 Apr;71(2):447-80
pubmed: 2006220
Neuron. 2010 Jul 15;67(1):49-60
pubmed: 20624591
Prog Retin Eye Res. 2003 Sep;22(5):607-55
pubmed: 12892644
Sci Transl Med. 2013 Jun 12;5(189):189ra76
pubmed: 23761039
Vis Neurosci. 2014 Sep;31(4-5):345-54
pubmed: 25100257
Mol Ther. 2014 Aug;22(8):1434-1440
pubmed: 24821344
Curr Biol. 2015 Aug 17;25(16):2111-22
pubmed: 26234216
Neuron. 2006 Apr 6;50(1):23-33
pubmed: 16600853
J Neurosci. 2008 Jul 30;28(31):7748-64
pubmed: 18667607
Nat Neurosci. 2008 Jun;11(6):667-75
pubmed: 18432197
Nature. 2003 Jul 3;424(6944):76-81
pubmed: 12808468
Front Neurosci. 2017 Mar 29;11:161
pubmed: 28424574
Prog Retin Eye Res. 2001 May;20(3):351-84
pubmed: 11286897
Science. 2010 Jul 23;329(5990):413-7
pubmed: 20576849
Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15012-7
pubmed: 22891310
Neuron. 2011 Feb 24;69(4):713-20
pubmed: 21338881
Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4611-6
pubmed: 15557474
Gene Ther. 2012 Feb;19(2):169-75
pubmed: 21993174
Mol Ther. 2019 Jun 5;27(6):1195-1205
pubmed: 31010741
PLoS Biol. 2015 May 07;13(5):e1002143
pubmed: 25950461
N Engl J Med. 2006 Oct 5;355(14):1474-85
pubmed: 17021323
Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):16009-14
pubmed: 18836071
Gene. 1989 Jul 15;79(2):269-77
pubmed: 2551778
Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1288-1294
pubmed: 29625451
EMBO Mol Med. 2016 Nov 2;8(11):1248-1264
pubmed: 27679671
Mol Ther. 2017 Nov 1;25(11):2546-2560
pubmed: 28807567
Neuron. 2006 Apr 6;50(1):1-3
pubmed: 16600846
Mol Vis. 2013 Jun 12;19:1310-20
pubmed: 23805038
Mol Ther. 2009 Dec;17(12):2096-102
pubmed: 19672248
J Comp Neurol. 2012 May 1;520(7):1406-23
pubmed: 22102216
Mol Ther. 2009 Mar;17(3):463-71
pubmed: 19066593
Lancet. 2006 Nov 18;368(9549):1795-809
pubmed: 17113430
Mol Ther. 2015 Oct;23(10):1562-71
pubmed: 26137852
Nat Commun. 2019 Oct 4;10(1):4524
pubmed: 31586094
PLoS One. 2013 Jun 14;8(6):e66332
pubmed: 23799092
J Neurosci. 2008 Dec 24;28(52):14282-92
pubmed: 19109509
Cell. 2018 Jul 12;174(2):465-480.e22
pubmed: 30007418
Front Cell Neurosci. 2018 Sep 21;12:316
pubmed: 30297985
ACS Chem Neurosci. 2014 Oct 15;5(10):895-901
pubmed: 25089879
Front Syst Neurosci. 2016 Sep 02;10:74
pubmed: 27642278
Vision Res. 2008 Feb;48(3):353-9
pubmed: 17923143
Gene Ther. 2012 Feb;19(2):162-8
pubmed: 21993172
Exp Eye Res. 2019 Jan;178:15-26
pubmed: 30218651
Mol Ther. 2011 Jul;19(7):1220-9
pubmed: 21505421
J Neurosci. 2009 Jul 22;29(29):9186-96
pubmed: 19625509
Gene Ther. 2016 Aug;23(8-9):680-9
pubmed: 27115727
Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3821-6
pubmed: 17652757
EMBO Mol Med. 2014 Aug 04;6(9):1175-90
pubmed: 25092770
J Comp Neurol. 2003 Jan 1;455(1):1-10
pubmed: 12454992
Nat Rev Neurosci. 2014 Aug;15(8):507-19
pubmed: 25158357
Mol Ther. 2015 Jan;23(1):7-16
pubmed: 25095892
J Comp Neurol. 1990 Nov 15;301(3):433-42
pubmed: 2262600
Annu Rev Vis Sci. 2015 Nov 24;1:185-210
pubmed: 28532375
Nat Commun. 2019 Mar 15;10(1):1221
pubmed: 30874546

Auteurs

Qi Lu (Q)

Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University School of Medicine, Detroit, MI 48201, USA.

Tushar H Ganjawala (TH)

Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University School of Medicine, Detroit, MI 48201, USA.

Andrea Krstevski (A)

Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University School of Medicine, Detroit, MI 48201, USA.

Gary W Abrams (GW)

Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University School of Medicine, Detroit, MI 48201, USA.

Zhuo-Hua Pan (ZH)

Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University School of Medicine, Detroit, MI 48201, USA.

Classifications MeSH